Article thumbnail

HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH)

By James E Boers, Harriëtte Meeuwissen and Natalie Methorst
Topics: Original Articles
Publisher: Blackwell Publishing Ltd
OAI identifier: oai:pubmedcentral.nih.gov:3085073
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2007). A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.
  2. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast
  3. (2005). Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.
  4. (1997). Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization.
  5. (1993). Amplification of the c-erbB2 gene in gastric carcinoma: correlation with survival. Oncology
  6. (2008). Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology
  7. (2009). Association of ERBB2 gene status with histopathological parameters and diseasespecific survival in gastric carcinoma patients.
  8. (2007). Close association between HER-2 amplification and overexpression in human tumors of non-breast origin.
  9. (2004). Coamplified and overexpressed genes at ERBB2 locus in gastric cancer.
  10. (2008). Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.
  11. (2008). EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev.
  12. (1994). erbB-2 expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection. Surgery
  13. (2007). Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction.
  14. (1994). Expression of c-erbB-2 oncogene product in Barrett’s adenocarcinoma: pathological and prognostic correlations.
  15. Expression of Her2/neu oncogene product p185incorrelationtoclinicopathologicalandprognosticfactorsof gastriccarcinoma.J.CancerRes.Clin.Oncol.1992;118;474–479.
  16. (2007). Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.
  17. (2005). Gastric adenocarcinoma: review and considerations for future directions.
  18. (2003). Gene amplification in esophageal adenocarcinomas and Barrett’s with high-grade dysplasia. Clin. Cancer Res.
  19. (2009). HER-2 amplification is highly homogenous in gastric
  20. (2000). HER-2/ neu gene amplification by FISH predicts poor survival in Barrett’s esophagus-associated
  21. (2006). HER-2/neu amplification is an independent prognostic factor in gastric cancer.
  22. (2007). HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.
  23. (2003). HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples.
  24. (2008). HER2 testing in the UK: further update to recommendations.
  25. (2008). HER2-positivity rates in advanced gastric cancer: results from a large international phase III
  26. (2008). Immunohistochemical antibodies in breast cancer HER2 diagnostics. A comparative immunohistochemical and fluorescence in situ hybridization study. Tumour Biol.
  27. (2006). Ohtsu A et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
  28. (2000). Pathology and genetics of tumours of the digestive system.
  29. (2008). Real time RT–PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with
  30. (2002). Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay.
  31. (2005). Targeted therapies for esophageal cancer. Oncologist
  32. (2001). The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest.
  33. (2006). Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization
  34. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet